Cell-Based Therapy for Necrotizing Meningoencephalitis in Pugs
ClosedDescription
Ethos Discovery proposes that the spontaneous, but strongly genetic-based model of canine Necrotizing meningoencephalitis (NME) presents a unique way to help demonstrate the feasibility of inflammatory neurological disease prevention therapy. We will utilize previously identified genomic markers of NME risk in pugs and administer cell-based immune-modulatory therapy in high-risk dogs to prevent or delay the onset of disease. The therapy will also be administered to symptomatic pugs to assess if it delays disease progression.
ELIGIBILITY CRITERIA
- TBD pending outcome of this related study